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From embodied risk to embodying hope: therapeutic experimentation and 
experiential information sharing in a contested intervention for Multiple 
Sclerosis 
People who pursue unproven therapies are often portrayed as ‘desperate’ individuals duped 
by medical racketeers peddling ‘false hope’. These patients, in contrast, present themselves as 
empowered citizens who have taken an informed decision to pursue an experimental therapy. 
This paper explores the latter perspective through the case of the so-called ‘liberation 
procedure’: a controversial endovascular intervention proposed as a treatment for Multiple 
Sclerosis (MS). Drawing on interviews with 48 people affected by MS, we analyse the 
decision-making processes and justifications thereof of those who had the procedure (n=31). 
While the decision to have the intervention might not have been justified according to the 
standards of evidence-based medicine, it was nonetheless premised on a shared ‘experiential 
logic’ – conceptualised as a logic of embodied risk/hope – that extends beyond the specific 
condition and therapy in question. The paper explicates this logic, concentrating on patients’ 
negotiations of: a) risk and uncertainty; b) expertise and evidence; c) hope and experiment. In 
particular, we foreground how, through a combination of therapeutic experimentation and 
experiential information sharing, patients turn their own bodies into (contested) sources of 
hope for themselves and others, which, in turn, shapes their embodied experiences of living 
with MS in the present.  
Key words: multiple sclerosis; hope; risk; experiment; evidence; experience. 
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1. Introduction 
People with incurable health conditions who pursue unproven therapies are often portrayed 
by the media, policy-makers, and expert scientific commentators as ‘desperate’ individuals 
duped by medical racketeers peddling ‘false hope’ (as opposed to the ‘realistic’ hope offered 
by evidenced-based medicine) (Petersen et al, 2015; Prasad, 2015). This is especially the case 
for those who travel abroad for controversial treatments not provided or sanctioned by their 
own country’s national healthcare system.1 In contrast, these patients present themselves as 
empowered individuals who have taken an informed decision to pursue an experimental 
therapy. With a few exceptions, focused mostly on stem cell therapies (Song, 2010; Petersen, 
et al, 2014; Prasad, 2015), there has been little in-depth empirical research into patients’ 
perceptions and experiences of such treatments. 
This paper contributes to social science research on people’s experiences of controversial 
therapies for conditions that conventional Western biomedicine has insufficient treatment 
options for. More specifically, it focuses on the case of people with Multiple Sclerosis (MS) 
who chose to undergo the so-called ‘liberation procedure’: an endovascular intervention, 
which was controversially proposed as a treatment for MS in 2009 (Zamboni et al, 2009a), 
prompting a wave of international patient activism and associated medical travel. Patients 
who resolved to have the liberation procedure were regularly framed, even by those 
sympathetic to their situation, as being led astray by dubious research, misguided activists 
and unscrupulous practitioners motivated by financial gain.2 This framing was challenged by 
a countervailing narrative in which, in newspaper and magazine articles, on television and the 
internet, and in interviews with us, the very same patients presented themselves as informed 
citizens who, let down by mainstream biomedical research and their national healthcare 
systems, were choosing to have an experimental therapy, fully cognisant of the risks involved 
and the uncertain nature of treatment outcomes. 
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Drawing on interviews with 48 people affected by MS, living in seven different countries 
(Canada, America, the UK, Australia, Israel, Ukraine, and Vietnam), we analyse how patients 
who had the liberation procedure described their decision-making processes (n=31). While 
the accounts we collected were personal and highly individual, there were striking 
commonalities in how interviewees explained the decision(s) they had taken. Our findings, 
furthermore, correspond closely with research on the experiences of patients with various 
other health conditions who similarly chose to have unproven therapies (Song, 2010; Petersen 
et al, 2014; Prasad, 2015). 
Through the analysis presented below, we show how, in the context of controversial therapies 
for unpredictable progressive diseases such as MS, decision-making involves uneasy 
negotiations around different forms of uncertainty. Patients and those close to them navigate 
these uncertainties through ‘weighing up’ competing claims about therapeutic risk, treatment 
efficacy, and potential health outcomes. For those who choose to pursue unproven therapies, 
this weighing up is premised on a therapeutic rationality very different to that found in 
mainstream biomedicine – one in which the shared experiential, and above all embodied, 
predicament of living with a particular condition is foregrounded. Thus we argue that while 
the decision to have an unproven therapy, such as the liberation procedure, might not be 
justified by the standards of evidence-based medicine, it is nonetheless premised on a 
particular ‘experiential logic’ that is not only shared by those undergoing the same treatment, 
but extends beyond any one specific therapy and condition.3  
In this paper we explicate some of the key terms of this logic, concentrating on how the 
people we interviewed: (a) negotiated various risks and uncertainties associated with life with 
MS and the liberation procedure specifically; (b) weighed up different forms of evidence and 
expertise to legitimise or delegitimise the treatment; and (c) understood the meanings and 
implications of hope in relation to the therapeutic experimentation they saw themselves as 
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engaging in. We conceptualise this logic as one of ‘embodied risk/hope’, in which, through a 
combination of therapeutic experimentation and experiential information sharing, patients 
come to ‘embody’ hope for themselves and others, counterbalancing the sense of embodied 
risk they live with on a daily basis.  
The interviews we draw on are primarily with patients who have had the liberation procedure 
(n=31), although we do occasionally compare their accounts with those who were either 
unable or chose not to undergo it (n=17). A substantial majority of our interviewees adopted 
a positive attitude towards the procedure and the research that supports it, while being openly 
critical of mainstream MS research, treatment and care. This represents only one partial side 
of an acrimonious public debate. It is not our aim here to analyse the debate around the 
liberation procedure; nor is it to assess evidence and endorse or condemn either position. 
Rather, we seek to explore the distinctive rationality underpinning decision-making in cases 
where people pay considerable sums of money to have unproven therapies, often traveling 
long distances, in contravention of the prevailing healthcare advice.4 This is a rationality 
which, we suggest, needs to be understood for what it is and taken seriously, rather than 
dismissed as ‘irrational’ or psychologised as ‘desperate’. 
Given the emphasis placed on patient choice in contemporary healthcare, as well as the rise in 
people choosing experimental therapies, it is essential that, as Alan Petersen and colleagues 
have argued, we explore not only how and why patients make such ‘choices’, but also how 
they experience and rationalise them (Petersen et al, 2014; p.681). In other words, what kinds 
of logics or rationalities underpin patients’ decision-making processes. Cases such as the one 
analysed in this paper provide opportunities for enhancing our understanding of the collective 
‘risk epistemologies’ patients develop alongside, within and, at times, in conflict with the 
wider anticipatory regimes that permeate contemporary biomedicine (Lupton and Tulloch, 
2002; Adams et al, 2009). At the same time, they have the potential to provide insights of 
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practical relevance to biomedical researchers, practitioners and policy-makers who are 
increasingly required to respond to controversial therapies such as the one described below. 
2. Multiple Sclerosis and the liberation procedure: background and context 
MS is the most common neurological condition to affect young adults and, although 
extremely unpredictable in terms of both symptoms and prognosis, for most people it is a 
progressive disease that results in some level of permanent, often severe, disability (Trojano 
et al, 2003; Compston and Coles, 2008). At present, there is no cure and although treatment 
options are available they are not suitable for all patients and are often accompanied by 
severe side-effects. Disease modifying drugs (DMD) have been shown to reduce relapses, but 
are less successful at altering the long-term progress of the disease and cannot reverse 
neurological damage (Compston and Coles, 2008). As a consequence, people with MS not 
only cope with changeable, extremely disruptive, symptoms and drug side-effects; they face 
an uncertain future with the prospect of declining health and mobility (for research on 
people’s experiences of MS see Stewart and Sullivan (1982), Robinson (1990), Hakim et al, 
(2000) and Lexell et al, (2009)). Unsurprisingly, there is a long history of MS patients turning 
to alternative and complementary medicine as well as heterodox and experimental therapies 
originating from within the (bio)medical sciences (Robinson, 1990; Bowling, 2011). The 
liberation procedure is one of the latest to emerge in the latter category.  
 
In 2009, Italian physician and former vascular surgeon Paolo Zamboni and colleagues 
published an article in the well-respected Journal of Neurology, Neurosurgery and Psychiatry 
which suggested that specific abnormalities in the jugular and azygous veins – what they 
termed chronic cerebrospinal venous insufficiency (CCSVI) – were strongly associated with 
MS (Zamboni et al, 2009b).5 Towards the end of the same year, the results of a prospective 
open-label study that used venous angioplasty – a relatively minor endovascular intervention 
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involving the insertion of a balloon catheter to widen stenosis (blockages) in veins – to open 
the jugular and azygous veins of MS patients diagnosed with CCSVI was published in the 
Journal of Vascular Surgery (Zamboni et al, 2009a). Based on research with 65 people with 
MS, the authors argued it was safe to perform angioplasty on people with MS and, moreover, 
that doing so was positively associated with better clinical and quality of life outcomes, 
especially in patients with the most common, relapsing remitting, version of the disease 
(Zamboni et al, 2009a). Thus, in addition to challenging the contested, but nonetheless 
predominant, theory that MS is an autoimmune disease, Zamboni proposed venous 
angioplasty – quickly dubbed the ‘liberation procedure’ by supporters – as a new treatment 
modality, arguing that it had the potential to relieve MS symptoms and alter disease 
progression (Zamboni et al, 2009a; Zamboni et al, 2009b).  
 
People affected by MS across the world responded to Zamboni’s research with considerable 
interest. Greatly aided by the use of social media, such as forums, Facebook and YouTube, 
within a very short space of time patients and their family members were searching for 
medical practitioners (primarily interventional radiologists) willing to perform the relevant 
tests and, if deemed necessary, treat them for CCSVI (Rhodes, 2011; p.15). Some patients 
were successful and soon they and their family members were sharing the names of 
sympathetic practitioners (Rhodes, 2011, pp.28-30). Patients who had the procedure were 
quick to communicate their experiences, and while not all of these were straightforwardly 
positive, many people reported dramatic improvements (Mazanderani et al, 2013; Gafson and 
Giovannoni, 2014; Koschack et al, 2015), with the widespread circulation of positive 
accounts further encouraging patients to have the procedure (Ploughman et al, 2014; Snyder 
et al, 2014; Sudau et al, 2014). 
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Despite the enthusiasm of patients and the support of a small, but in some cases high-profile, 
group of biomedical scientists, radiologists and vascular surgeons, the majority of 
neurologists were vocally sceptical about CCSVI and its putative association with MS 
(Doepp et al, 2010; Mayer et al, 2011; Baracchini et al, 2012; Reekers, 2012). Furthermore, 
they raised serious concerns about the risks of performing angioplasty on the neck veins of 
MS patients. For, although angioplasty is a well-established, almost routine, intervention in 
other parts of the body, it is not typically done in the veins of the neck, and, prior to 
Zamboni’s research, it had certainly not been considered a therapy for MS. Concerns about 
the safety of the procedure were bolstered by reports of complications experienced by some 
patients and by the fact that a few people died after having stents inserted in their veins. 
Consequently, national MS Societies, MS researchers and health regulators (such as the 
National Institute of Clinical Excellence (NICE) in the UK, the Food and Drug 
Administration (FDA) in the USA, and the Canadian Institute of Health Research (CIHR)) 
stated that CCSVI and the liberation procedure was not supported by scientific evidence, and 
venous angioplasty should only be performed on MS patients as part of appropriately 
designed research studies.6 As a result, interventional radiologists who had initially been 
willing to provide the procedure in countries such as Canada, the USA and Australia were 
deterred from doing so, making it increasingly difficult for patients to access either testing or 
treatment in their own countries.   
This prompted an angry response from patient groups, triggering a groundswell of 
international CCSVI patient activism, with people affected by MS petitioning their healthcare 
providers, national MS Societies and politicians for the liberation procedure to be made 
available in clinical studies or on compassionate grounds (Laupacis and Slutsky, 2010; Chafe 
et al, 2011). However, as the procedure was (and remains) not available through the national 
healthcare systems of most countries – including Canada, which emerged as a fulcrum for 
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patient activism – thousands of people travelled to private clinics (e.g. in Poland, Bulgaria, 
India, Costa Rica) or, where possible, took part in research studies (e.g. in the USA and Italy) 
in order to have venous angioplasty.  
To date, numerous studies, spurred on and even funded by patient activism, have been 
conducted on the association between CCSVI and MS. Zamboni’s initial findings have not 
been replicated and the consensus within mainstream medicine is that if CCSVI does exist as 
a distinct syndrome it is not causally related to MS. This would make the liberation 
procedure, at best, a placebo, and, at worst, dangerous for patients (Doepp et al, 2010; Mayer 
et al, 2011; Traboulsee et al, 2014; Tsivgoulis et al, 2015). Yet despite the biomedical 
establishment repeatedly announcing CCSVI’s ‘death knell’ (Stolz, 2015), a cohort of 
scientists continues to pursue research on the vascular dimensions of neurological diseases, 
including MS, and have created a society devoted to this endeavour (https://isnvd.org). 
Moreover, many people with MS who have undergone the procedure feel that they benefited 
from it and an international contingent of patient activists are still advocating for further 
research into the role of the vascular system in the disease.7 
3. Methods 
Recruitment, Sampling and Data Collection 
This paper is based on an analysis of qualitative interviews with 48 people affected by MS 
(see Table 1). These interviews were conducted as part of two separate projects. The first 
project, which took place in Canada (July-November 2011), explored how people with MS 
used online resources to learn about CCSVI and how these practices informed their decision 
to pursue the liberation procedure. The second project, which took place in the UK 
(November 2011-August 2012), explored how people affected by MS used internet 
technologies, with a specific emphasis on the seeking and sharing of experiences. While the 
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liberation procedure and CCSVI were not the key focus of the study, it was being widely 
discussed online at the time and interviewees were explicitly asked about their opinions on 
and experiences of it.  
Participants for both studies were recruited online. For the Canadian study, the research was 
advertised on: the CCSVI discussion board on a patient-led forum for people affected by MS, 
www.thisisms.com (TIMS); the Facebook page of the Alberta Chapter of the Multiple 
Sclerosis Society of Canada; the website and Facebook page of Direct MS, a non-profit 
organization that was supportive of CCSVI. The UK study was advertised on: the research 
web-pages of four UK-based MS charities – the MS Society, the MS Trust, the MS Resource 
Centre (now MS-UK) and Shift.MS; the blog of the Berkshire MS Therapy Centre; the 
mailing lists of regional branches of the MS Society. One interviewee was contacted directly 
via an e-mail address provided on her YouTube channel.  
All participants were given written information about the projects, and informed consent was 
obtained via e-mail. The interviews for the UK project were conducted over the telephone 
and lasted for approximately one hour; they were audio recorded and transcribed verbatim. In 
order to afford participants an added layer of anonymity, the Canadian study used online 
asynchronous interviews (Berg, 2009; p.126). Due to the perceived anonymity of the medium 
and the fact that participants can take their time to think through their responses, 
asynchronous interviews can generate very open and forthright answers (Hamilton and 
Bowers, 2006; McCoyd and Kerson, 2006). They can also facilitate access to hard-to-reach 
and geographically dispersed populations that may not traditionally participate in research 
(Wilkerson et al, 2014), something that was particularly appropriate for a controversial topic 
such as CCSVI.  
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For the asynchronous interviews, interviewees were emailed the interview protocol by the 
primary researcher (JK), which they then filled out and returned at their convenience. Once 
the interview was returned, participants were asked if the researcher could contact them 
within three months for any further questions or clarifications. Follow-up questions based on 
key emergent themes were then emailed to participants during the data analysis phase. These 
questions were used to build a richer understanding of participants’ experiences of MS, being 
tested for CCSVI and, if relevant, having the liberation procedure. Nine participants 
responded to the follow-up questions via email. Asynchronous interviews can offer as rich or 
even richer detail than face-to-face or telephone interviews through follow-ups with the 
participant that may not be possible with more traditional qualitative data collection methods 
(Hamilton and Bowers, 2006; McCoyd and Kerson, 2006; Ratislavová and Ratislav, 2014). 
This was the case in the interviews collected in the Canadian study where participants 
provided very detailed descriptions of their experiences, often reflecting in-depth on the 
questions posed to them.  
Ethical approval for the Canadian study was received from the University of Calgary 
Conjoint Faculty Research Ethics Boards. Ethical approval for the UK study was received 
through the University of Warwick’s Biomedical Research Ethics Committee.  
Combined Analysis  
Between March and August 2015, the primary researchers on the two studies (JK for the 
Canadian study and FM for the UK study) re-analysed the entire interview corpus. As the 
liberation procedure and CCSVI were a topic of interest in both sets of interviews, this was 
not strictly speaking a secondary analysis, which is usually understood as analysing 
qualitative data for a purpose other than what it was originally collected (Heaton, 2004). 
Instead, our aim was to combine, compare and contrast the findings from the two projects in 
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order to develop empirically grounded insights on the decision-making processes and 
practices relating to the liberation procedure from the perspective of people with MS.  
As neither study had ethical approval to share entire interviews outside the initial project 
team, JK and FM revisited their respective transcripts independently. First, we organised the 
contents of our interviews into six descriptive categories that roughly mapped on to what we 
conceptualised, both literally and figuratively, as interviewees’ treatment ‘journeys’: initial 
exposure and response to CCSVI as a theory and the liberation procedure as a potential 
therapy; perceptions of the CCSVI debate and the key stakeholders involved (e.g. 
neurologists, MS Societies, interventional radiologists etc.); deciding whether to be tested for 
CCSVI and/or to have the liberation procedure; actual experiences of being tested and/or 
having the intervention; reflections on treatment outcomes, including whether they perceived 
it as being successful or not; thoughts on the future of CCSVI research and treatment. These 
categories were then shared and discussed by all authors. Next, we performed a detailed 
thematic analysis within and across the categories. Here, we focused on how interviewees 
who had had the liberation procedure described and justified their decision(s). Each 
researcher took primary responsibility for analysing their own interviews, comparing notes 
and sharing codes. All notes and codes were reviewed by AD, who is very familiar with the 
interviews from the Canadian study. The findings and themes were extremely consistent 
across both data sets.  
Three core factors emerged as particularly significant in terms of influencing the decision to 
have the liberation procedure: the first was how interviewees’ interpreted and assessed the 
various risks and uncertainties they have to navigate in relation to the procedure and life with 
MS more generally; the second, how different forms of expertise and evidence were 
evaluated and prioritised in their decision-making processes; three, how both of the above 
were mediated by a specific orientation towards hope, which was bolstered through patients’ 
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experiential information sharing practices and online community dynamics. While these 
factors did not operate in isolation and were closely interrelated, we have separated them out 
for analytical purpose, both here and in the discussion below. 
4. ‘Waiting for a bomb to go off in your brain’: existential uncertainty, 
embodied risk, and the liberation procedure 
The majority of people we spoke to who had had the liberation procedure suffered from an 
aggressive form of MS, with frequent and/or severe relapses. They felt the disease was 
progressing rapidly and were already experiencing disabling symptoms and deteriorating 
health. Loss of mobility was one of the most frequently mentioned and, arguably, most feared 
symptom, with one participant describing himself as “chased by a monster called wheelchair 
bound.” Our interviewees were also very concerned about what, from a clinical perspective, 
are not typically considered the disease’s most disabling symptoms, such as fatigue, cognitive 
impairment, and emotional changes (Rothwell et al, 1997). Alongside more overt 
manifestations of the disease, these subtle, pervasive and hard to define symptoms limited 
their ability to live what they considered a normal life – for example, altering their capacity to 
work, be a parent, and engage in activities they not only enjoyed, but defined them as a 
person.  
A core theme that emerged from our analysis was what, in research on other chronic 
illnesses, has been conceptualised as ‘existential uncertainty’: the feeling that one’s body, life 
and sense of self are persistently under threat (Adamson, 1997, p.134). What is more, rather 
than being external to them, emerging from the environment or a consequence of their 
lifestyle, this threat was ‘embodied’ (Kavanagh and Broom, 1998, p.438), with patients’ own 
bodies perceived as posing a constant, if at times latent, risk to their quality of life. In the 
words of one interviewee, a young mother with two children, living with MS was like 
“waiting for a bomb to go off in your brain all the time.”  
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This risk was not something they felt able to mitigate with mainstream medicine. Quite the 
opposite – those on medication spoke of struggling with side-effects and expressed 
considerable concern about future ones. Tysabri,8 a DMD used in cases of aggressive MS, 
was referenced particularly frequently because its side-effects can be fatal. More generally, 
many interviewees said they had exhausted all available mainstream biomedical options:  
None of the current meds worked for me – I took Copaxone injections for years, 
followed by Rebif injections… my last MS med was chemotherapy in 2009, but as I 
mentioned earlier I had already experienced a decline in heart function, so I stopped. 
Nothing more was available. [Interviewee #8: A Canadian man who had venous 
angioplasty in Poland. He felt that the intervention improved his mobility and overall 
wellbeing].  
Many of these patients had also pursued alternative or complementary therapies, such as 
hyperbaric oxygen therapy, dietary restrictions, vitamins and supplements, or low dose 
naltrexone (LDN).9 These therapies are mostly palliative and make no claims about MS as a 
disease. They are consequently usually accepted as relatively harmless, i.e. low risk, ways for 
patients to, at least potentially, relieve some of their symptoms and improve their sense of 
wellbeing. They are all, nonetheless, unproven and as such indicative of a wider context in 
which patients with MS experiment therapeutically, and in many cases are not averse to 
pursuing more radical treatment options, such as the liberation procedure.10 
For, while neurologists and other medical specialists queried the science underpinning 
CCSVI, foregrounding both the risks associated with the procedure and uncertainties about 
its therapeutic outcomes, our interviewees emphasised the profound existential uncertainty of 
living with MS and the embodied risks, both psychological and physical, they associated with 
‘doing nothing’ and letting the disease progress unchecked. Given the progressive and 
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unpredictable nature of MS, they believed that they simply could not afford to wait for 
biomedical science to follow through on large-scale double-blind randomised control trials 
(for similar arguments in relation to other conditions see Epstein (1995), Callon and 
Rabeharisoa (2003), Novas (2006) and Prasad (2015)). Instead, they felt they had to take 
action and do everything in their power to halt, prevent or minimise future deterioration now 
with the, albeit imperfect, knowledge available to them. From this perspective, the liberation 
procedure was seen as simultaneously a risk and a strategy of risk mitigation. 
In addition to contrasting the risks of the liberation procedure with the embodied risks of MS, 
interviewees compared, usually favourably, the riskiness of balloon angioplasty with that of 
mainstream MS drugs. For example: “Three people have passed away since having CCSVI 
treatment, but there are literally hundreds of people who have passed away because of MS 
drugs” [Interviewee #38: An Australian woman treated in Australia. Her MS was very 
aggressive and she felt a major improvement in her symptoms and overall wellbeing]. This 
was further bolstered by the argument that angioplasty is hardly experimental in and of itself, 
as it is carried out regularly for conditions other than MS: “This is NOT a new procedure. It 
is performed daily in our hospitals just not on MS patients” [Interviewee #27: A Canadian 
woman who had the procedure in the US. She felt that she had considerable improvement in 
her mobility and a number of other symptoms such as fatigue, pain and balance]. Stenting 
was considered more dangerous and patients were aware of the increased risks associated 
with it. However, even here, some people, such as the woman quoted below, thought the 
benefits of keeping the veins open outweighed the risks:  
I feel I am still doing very well because of that [having a stent]. Many refused a stent 
and have subsequently re-stenosed and their symptoms have returned. [Interviewee 
#13: A Canadian woman who was treated in Poland. She felt that her symptoms and 
overall wellbeing had improved]. 
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Here, the increase in risk associated with a more invasive intervention was, to a degree, 
correlated with greater efficaciousness and ultimately better outcomes. The relative 
routineness and hence ‘safety’ of the procedure itself was, furthermore, not the only factor 
patients considered when assessing risk. Who performed it was vitally important: 
What was most clear was that the risks of treatment were minimal and the potential 
benefit if it did stop MS progression and/or eliminate some of its side effects were 
such that there was no question that treatment made sense, IF the right IR 
[interventional radiologist] could be found to do the treatment. [Interviewee #4:  An 
Israeli woman who was treated first in Poland and then the USA. She felt that her 
symptoms improved after the first intervention, but that they worsened after the 
second. Emphasis her own].  
Patients who had undergone the procedure shared experiences of being treated by particular 
radiologists and surgeons, a number of whom were rated especially highly. Their reputation 
was only in part due to their qualifications and experience as surgeons or radiologists. 
Arguably more important was their prominence online, publications on CCSVI, 
endorsements by patients, their own direct participation in online discussions (e.g. on TIMS 
or YouTube), and how promptly and thoroughly they responded to email queries. 
Interviewees repeatedly emphasised that these were highly trained medical experts in whose 
qualified opinion venous angioplasty was a reasonable intervention for someone diagnosed 
with a blockage in their veins. They thereby shifted the locus of their risk assessment from 
the intervention itself to the expertise of the practitioner performing it (discussed in more 
depth in the next section).  
Where the procedure would be performed was a related consideration, with treatment closer 
to home considered less risky. Those who were treated in their home countries thought that 
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not having to travel abroad minimised physical strain and ensured continuity of care, while 
those who did travel internationally relied most of all on the recommendations of fellow 
patients who had undergone the procedure.  
Like patients travelling for stem cell therapies (Petersen et al, 2014, p.678), the financial risks 
of the procedure were as much, if not more, of a concern than the medical ones. Depending 
on location, practitioner and the number of angioplasties or stents required, the cost of the 
procedure ranged from US $10,000 to US $15,000, excluding transport and accommodation. 
This is not a negligible sum and cost was unquestionably a barrier. Nine interviewees who 
had not had the intervention said that this was because they could not afford it, rather than 
because they were sceptical about its scientific validity or worried about its safety. Those 
who did have it, often with the financial support of family and friends, recognised that it was 
expensive and took various factors into consideration when deciding whether it represented 
value for money. They compared the cost with that of other therapeutic options, pointing out 
that it was considerably cheaper than some alternatives, such as stem cell therapies. They also 
stressed that MS was an expensive condition to live with, rationalising the cost of the 
procedure against expenses they already faced or were likely to face in the future, such as 
converting their bathroom or buying a mobility scooter. 
However, our interviewees’ willingness to part with a substantial sum of money for an 
unproven therapy was less an indication of their faith in the procedure’s potential to improve 
their health, or of their readiness to subject themselves to a certain level of risk, and more the 
outcome of a complex process of weighing up of, on the one hand, the embodied risks they 
already lived with and, on the other, their ability to carry the financial risk of paying for an 
intervention with extremely uncertain outcomes.  
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5. Which expert? What evidence? Perceptions of professional jurisdiction, 
evidentiary regimes and empathetic care  
Although the liberation procedure was not endorsed by the vast majority of biomedical 
experts, patients who chose to have it did not reject the authority of biomedical expertise as 
such (as can sometimes be the case with those opting for ‘alternative’ therapies). Reputable 
journals had initially published encouraging research about CCSVI (for a review see 
Laupacis et al, 2011). The theory built on pre-existing vascular theories of MS (Nicolson and 
McLaughlin, 1988; Wong et al, 2012) and was supported by, at least some, biomedical 
scientists. Thus, patients needed to negotiate disagreements about this therapy within 
biomedicine and, more specifically, between (most) neurologists – the primary medical 
discipline that deals with MS – and a small, but vocal, contingent of interventional 
radiologists, surgeons, (a few) neurologists and other biomedical scientists who were 
supportive of, or at least interested in, the theory. When justifying their decision(s) to have 
the procedure, our interviewees emphasised jurisdictional divisions between medical 
specialisations, arguing that they were simply prioritising the expertise of one set of experts 
over another. For example: “This is a vascular issue and neurologists have no right in 
expressing their biased views as to whether I get my veins treated or not” [Interviewee #27]. 
This prioritisation of the expertise of radiologists and other vascular specialists over that of 
neurologists when it came to knowledge about the vascular system, was situated within a 
more extensive critique of neurology.11 Most of the patients we spoke to who had had the 
procedure expressed profound dissatisfaction with mainstream MS medicine, and with 
neurologists in particular. Their frustration, and in some cases anger, was based both on 
negative experiences with specific neurologists and on their disappointment with MS 
research, treatment and care more generally, especially with what they perceived as the 
neurologists’ domination of it. Interviewees were unhappy with the choice of treatments that 
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their neurologists were able to offer them and they also complained of not being treated either 
empathetically or holistically. They said they felt patronised, disempowered, and not listened 
to. They were especially frustrated by the constraints imposed on the types of research being 
pursued, by the slowness of therapeutic innovation and by the relative narrowness of 
approach, which they saw as prioritising the auto-immune theory of MS. They often blamed 
this on the influence of the pharmaceutical industry. 
I dealt with the MS Clinic for 8 years. I found them to be condescending and 
depressing.  In my opinion they had their own agenda and it was not always in my 
best interests.  I no longer see a neurologist – I found they were more interested in 
pushing drugs than listening or trying to find solutions. [Interviewee #13]. 
Many patients discussed CCSVI with their neurologist. A small number received a neutral or, 
rarely, positive response. For the most part, though, their neurologist was critical of the 
research and strongly recommended they not pursue venous angioplasty as a therapy for their 
MS: 
When I brought up the subject of CCSVI with the neurologist I was seeing, he had 
three stacks of photocopied ‘articles’ (negatively written, to ‘disprove’ CCSVI) on his 
desk, that he had ready to hand out to any of his patients who dared to show any 
interest whatsoever in the CCSVI angioplasty procedure. [Interviewee #32: A 
Canadian woman who had the intervention in Mexico. She did not feel that any of her 
symptoms improved, but she still recommends it to others in case it helps them].  
For many people, responses such as the one described above reinforced a perception that their 
neurologist did not have their best interests at heart, and was enforcing the status quo without 
being able to offer effective alternatives. Some interviewees, especially if they were already 
critical of mainstream MS medicine or had a troubled relationship with their neurologist, felt 
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anger at such responses. While others, pre-empting a negative response, chose not to tell their 
neurologist that they were considering having the procedure and, in some cases, never 
informed them after they had it.  
It is important to note that patients who chose not to have the procedure typically expressed 
rather different sentiments about mainstream MS research, treatment and care, and reported 
more positively about their interactions with neurologists. This was especially the case with 
patients who were sceptical of CCSVI and who voiced criticism of the ‘hijacking’ of the MS 
research agenda by a ‘pro-CCSVI lobby’. For them, the fact that their neurologist was not 
convinced by CCSVI was one of the key reasons they chose not to pursue the liberation 
procedure (for a review of how doctor-patient relationships can influence patient decision-
making and outcomes see Ong et al (1995)).  
What was at stake here, however, was not simply patients deciding to privilege one set of 
experts over another (essentially because they felt disappointed by one, older, established 
therapeutic promise, while being encouraged by another, newer, untested one). What was 
being weighed up and decided between were different types of evidence for what counted as a 
legitimate and efficacious therapy – what, drawing on the work of Tiago Moreira and Paolo 
Palladino (2005), can be thought of as related, yet distinct, ‘regimes of truth’.12 For, whereas 
the neurologists who critiqued the liberation procedure rejected findings that were not based 
on double-blind randomised control trials (the ‘gold-standard’ when assessing biomedical 
interventions), the surgeons and radiologists who defended the procedure put forward 
observational studies of individual outcomes (conforming with the standard of evidence often 
used in surgical disciplines (Meakins, 2002)). The relative merits of these different 
evidentiary regimes and their appropriateness for assessing the liberation procedure were 
frequently discussed in interviews. For example: 
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And the thing is, in radiology, procedures aren’t developed through double blind 
trials. The problem is neurologists are in the drugs mind-set […] I know enough about 
clinical trials and how you blind them to know you can’t blind this procedure to an 
awake patient. You can feel the balloon blowing up. I’ve done it twice, I know. 
[Interviewee #5: A British man who had venous angioplasty twice, once in Greece, 
once in the USA. He felt improvement in some of his symptoms, but not his 
mobility]. 
The kinds of evidence generated from observational studies supported by the defenders of the 
liberation procedure was, moreover, better aligned with the experiential logic of embodied 
evidence (discussed in more detail in the next section), which patients continually emphasised 
in their own understanding of therapeutic efficacy (emblematised, for instance, by their 
posting before-and-after-treatment self-monitoring videos on YouTube). The regime of truth 
privileged by the neurologists (which enjoys greater currency in biomedical science more 
generally), was, by contrast, perceived by patients as alienating, disempowering, and 
‘depressing’. This regime of truth and associated care practices, from their perspective at 
least, appeared to serve the interests of ‘big science’ rather than those of the living, highly 
individual, patient. 
Even though our interviewees were well aware of the large body of research that refuted the 
association between MS and CCSVI, they downplayed its significance by: a) raising doubts 
about the integrity of the researchers conducting such studies (e.g. highlighting their assumed 
close relationships with pharmaceutical companies); b) claiming they had a pre-existing bias 
(e.g. arguing that the researchers’ original training prevented them from making the radical 
move of questioning the auto-immune theory of MS); and c) challenging the design and 
management of these studies (e.g. querying the methods and equipment used, or questioning 
how closely the researchers had adhered to Zamboni’s protocol). Our interviewees 
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(especially, but not exclusively, those who had not had the procedure), did question the 
integrity of interventional radiologists offering the intervention. Here, a distinction was made 
between interventional radiologists motivated by financial gain versus those perceived as 
genuinely wanting to help patients. The latter was ascertained through assessing whether they 
were: conducting and publishing research on CCSVI (even when patients paid to take part in 
the research); interacting with and recognised as legitimate by prominent figures, such as 
Zamboni; engaging directly and actively with patients (e.g. by contributing to online forums 
and discussions); rated as supportive providers of high quality care (by receiving positive 
feedback from other patients). 
In debating and weighing up different forms of expertise, evidence, and care, patients (or 
their family members) became avid researchers, compiling and analysing the wide range of 
sources and types of information available on the internet. This contributed to the creation of 
knowledgeable and highly influential people affected by MS, either patients or their family 
members, with ‘lay expertise’ similar to that which has been documented in relation to other 
conditions (Epstein, 1995; Caron-Flinterman et al, 2005; Sosnowy, 2014). These expert 
patients were often also treatment pioneers and, therefore, not only disseminated research 
articles and ideas, but shared their experiences of the procedure. This powerful combination 
of, on the one hand, ‘interactional expertise’, the ability to intelligently discuss a domain of 
knowledge, without necessarily being a practitioner in it (Collins and Evans, 2002) and, on 
the other, a personal (indeed embodied) experience of both the disease and the intervention 
played a highly significant role, often influencing other patients’ decisions, as discussed in 
more depth below.  
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6. ‘Spreading hope around’: therapeutic experimentation, social media and 
experiential information sharing 
The CCSVI theory and associated liberation procedure generated considerable hope amongst 
MS patients and their families, with our interviewees frequently stating that it had been a long 
time since they had felt as hopeful about a new therapy. Nonetheless, none of them thought 
the procedure would be a miracle cure. Rather, they hoped for more modest improvements, 
such as the restoration of a lost function, the minimisation of existing symptoms, and 
especially the prevention of future deterioration (this echoes related studies, such as Petersen 
et al (2014, p.675) and Prasad (2015, p.143)). What is more, our interviewees recognised that 
venous angioplasty was unproven as a treatment for MS, but, crucially, were willing to 
experiment with it: 
My rationale was that even if it did not help me…I tried! And if it did, I could help 
move the research forward …for my kids and grandkids to hopefully never have to 
deal with this thing called MS. [Interviewee #24: An American woman who was 
treated in the USA. She felt that after the intervention she had improvement in her 
sensory perceptions and less pain].  
Their hope, in other words, resided not in some encouraging evidence of provable positive 
outcomes, but in the unpredictable ranges of possibilities that ‘experimentation’ as such 
entailed. Put differently, experimentation with their own bodies became a mechanism for, 
quite literally, ‘embodying’ hope. As illustrated in the quotation above, in a few cases, this 
experimental openness was linked to a more wide-ranging desire to contribute to scientific 
research on MS and to help future generations of people with the condition, including, 
potentially, their own children.13 
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By the time we spoke to them, our interviewees had already had a certain amount of time 
(from three months to two and a half years) to assess whether they felt the intervention had 
been successful for them. The vast majority reported positive outcomes – most frequently: 
improved balance, vision, cognitive function and/or bladder control, reduced fatigue, pain, 
heat sensitivity and/or stiffness. Many of these changes appeared, on the face of it, to be 
relatively minor, but for the people experiencing them even small improvements were 
deemed life-enhancing. When patients shared their experiences with their neurologist they 
felt that their improvements were downplayed or dismissed as a placebo effect, which they 
found upsetting and which further contributed to the breakdown in patient-doctor relations. 
This is very consistent, again, with patients’ experiences of stem cell therapies (Petersen et al, 
2014, p.679). 
Of course, numerous factors, including the relationship with and trust in the administering 
physician or surgeon, influence both patient perceptions of treatment success and more 
objective health outcomes (Di Blasi et al, 2001). This is further complicated by the fact that 
the most common version of MS is characterised by naturally occurring cycles of active 
(relapsing) and inactive (remissive) disease, while surgical interventions are particularly 
prone to placebo effects (Johnson, 1994; Shapiro and Shapiro, 1997, p.22). What is 
significant here is not that patients made claims about the treatment’s efficacy expressed in 
terms of both identifiable outcomes and improvements in their overall sense of wellbeing, but 
that these claims were supported by a swathe of experiential reports shared online (on TIMS, 
Facebook, blogs, YouTube etc.). These personal accounts went into considerable detail about 
the effect that having the procedure had on patients’ everyday life and struggle with MS, and 
resonated strongly with other patients (Vera et al, 2012; Mazanderani et al, 2013; Sudau et al, 
2014; Koschack et al, 2015). Often dismissed by medical commentators as ‘anecdotal’, 
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‘biased’ and ‘subjective’, such experiential accounts are, nonetheless, a major reason patients 
choose to pursue experimental therapies (Whelan, 2007; Song, 2010; Prasad, 2015): 
But to me you know watching people like Denise Manley [Canadian CCSVI activist 
with a YouTube channel] doing her videos and stuff like that it was like, do you know 
what that’s good enough for me, that shows me that this is worth looking at. 
[Interviewee #37: A British woman who had the intervention in the UK. She felt that 
if anything she only had some very minor improvements]. 
As illustrated above, videos where patients not only discussed, but visually displayed 
improvements in their symptoms, such as mobility, balance and cognitive function, were 
particularly powerful (Mazanderani et al, 2013). The use of patient testimonials was quickly 
taken up by private clinics as part of their advertising campaigns. They also featured in media 
reports, including a Canadian documentary about Zamboni’s research, which was widely 
circulated online, with subtitles in a variety of languages.14 Alongside video ‘evidence’ of 
this nature, patients shared venographic images, detailed, occasionally also videoed, 
descriptions of having the intervention, and information about their wider medical history. 
The most prolific sharers of experiential information of this nature kept textual or video 
diaries that spanned years, with an audience of regular viewers numbering in the thousands. 
This often inspired others to emulate the practice and share their own videos and other 
information, thereby turning their own bodies and experiences into a source of hope for other 
patients.  
Patients who did not have such good experiences with the liberation procedure were far less 
likely to share them (something not specific to this therapeutic intervention), and a bias 
towards positive reporting was openly acknowledged:  
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In forums such as This Is MS and Facebook, the information presented is generally 
skewed toward positive reports without representative negative reporting. That’s 
natural. Those who benefit are happy to take the time to tell others about the success 
of the procedure while those who don’t benefit, mostly move on since this is yet 
another treatment that failed to improve their MS. [Interviewee #4]. 
Many reasons were given for this, but an important one was the reluctance of patients to 
dampen another’s hope, something that was presented by some as a betrayal of fellow MS 
patients. CCSVI community organisers and patient activists did attempt to mitigate the bias 
towards the reporting of positive outcomes through collecting patient experiences more 
systematically. They worked hard at aggregating and (re)distributing experiential findings in 
a manner that showed an understanding of, but did not necessarily adhere to, standard 
biomedical methods for generating scientifically valid knowledge about therapeutic risk and 
effectiveness. This was done, for example, through a structured thread on TIMS where users 
were asked to document negative experiences. Another example is the CCSVI tracking 
website (http://ccsvi-tracking.com), which was designed to record and visualise patient-
reported outcomes. Despite such attempts at providing a more balanced perspective, the sheer 
number of positive accounts circulating online undoubtedly influenced patients’ decision-
making: “The optimistic, encouraging outcomes helped me make my decision to go have it 
done. I figured THAT many positives couldn’t possibly be the placebo effect” [Interviewee 
#20: A Canadian woman who was tested in the USA and treated in Costa Rica. She felt that 
she had some minor improvements in her symptoms, is happy she had the procedure and 
recommends it to others. Emphasis her own]. 
Hope was not generated, however, solely through the visibility of positive stories. Equally 
important were the practices of researching different treatment options and sharing 
experiences about their effectiveness, even when these were potentially in doubt. Indeed, 
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hope here was not an individual affective state or attitude but a practice requiring (if it was to 
be maintained) continuous affective labour (Miyazaki, 2004) or, in the words of Cheryl 
Mattingly, a ‘strenuous moral project’ (Mattingly, 2010, p.3).  This orientation towards hope 
was eloquently articulated in a YouTube video titled ‘About Hope’ posted by a young 
Australian woman whose YouTube channel contained some of the most widely viewed 
CCSVI videos: 
I guess what CCSVI did for me was just give me a little spark to believe that my 
future could be different and even if it is just a belief and it changes our concept of 
our future, even that helps our health […] Our state of mind if we have no hope is 
very different from if we do and to have that hope taken away or suppressed or to be 
told that there is nothing in this takes away something fairly significant for us as 
people with MS. So I don’t apologise for spreading hope around even if this hope […] 
gets proven to be an absolute placebo effect and this is just a coincident that so many 
people are feeling better. [YouTube video transcribed by researcher].15  
Thus, in the case of the liberation procedure, the moral project of cultivating hope took the 
form of therapeutic experimentation combined with in-depth experiential information 
sharing, skewed towards the reporting of positive results. Through a complex array of 
practices, technologies and discourses (from undergoing the procedure itself to posting videos 
of themselves online after treatment) patients turned their bodies and their experiences into 
‘experimental data’ and (at the very same time and by that very fact) came to embody hope 
for themselves and others (for very similar practices in relation to foetal-cell transplant 
treatment for Spinal Cord Injury (SCI) see Song (2010, p.390)). 
This embodiment of hope was multi-facetted. First, as described above, it was premised on 
the widespread, digitally mediated, textual and visual, performance of hope through 
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undergoing and sharing individual therapeutic experiences and outcomes. Second, as positive 
accounts of the liberation procedure amassed online, a wider corpus of experiential 
‘evidence’, collected and linked through forum threads, Facebook postings, and YouTube 
channels, came to embody hope for people affected by MS across the world. This, in turn, 
encouraged patients to share their experiences, thereby contributing to a recursive 
(re)articulation of hope as a means of challenging the pervasive sense of embodied risk and 
despair felt by many people with MS. Third, hope was embodied in that, as with other 
anticipatory modes of being, it was lived and felt in the present and, as such, had a tangible 
effect on people’s sense of self and wellbeing, regardless of any measurable clinical 
improvements (Adams et al, 2009, p.248).  
7. From embodied risk to embodying hope: discussion and conclusion  
Fear about how MS might affect them in the future, the degenerative nature of the condition, 
a lack of viable treatment options, and ambivalence about the state of mainstream MS 
research, treatment and care, all contributed to patients’ decision to pursue the liberation 
procedure. Far from being naïve about the lack of scientific evidence supporting CCSVI, the 
majority of our interviewees readily acknowledged that CCSVI as a theory and the liberation 
procedure as a treatment were still unproven and that therapeutic outcomes remained 
uncertain.  
It is widely recognised that many people at risk of or diagnosed with a serious illness, 
especially an unpredictable one such as MS, live with a sense of ‘embodied risk’, in which 
their own bodies are seen as posing a latent threat to their health and wellbeing (Kavanagh 
and Broom, 1998). People respond to such embodied risk in multiple ways: changing their 
lifestyle (e.g. eating healthily, exercising, reducing stress); engaging in self-assessment and 
surveillance (e.g. going for regular medical tests, engaging in informal self-monitoring 
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practices); taking pharmaceutical, surgical or prophylactic measures; turning to 
complementary or alternative medicine; or indeed, by actively resisting (e.g. deliberately 
ignoring) their status as someone ‘at risk’.  
In this paper we outlined how ‘embodied risk’ coupled with a) a profound sense of 
‘existential uncertainty’, b) the perceived ‘failure’ of mainstream biomedicine to provide 
viable therapeutic options, and c) the emergence of an alternative theory and associated 
experimental procedure rooted in an explanatory model and therapeutic logic (an 
endovascular intervention) that explicitly contrasted with the currently available options – all 
contributed towards encouraging some patients with MS to have the liberation procedure. For 
the most part these patients were well-informed and carefully weighed up various medical, 
personal and financial factors before deciding to have it. We have discussed how they 
negotiated and rationalised this decision around different kinds of risks associated with the 
intervention and conflicting forms of evidence for its efficacy.  Furthermore, we described 
how hope was: a) seen as a value in its own right in the experiential rationality of patients; b) 
deployed as an important factor in the decision-making processes that led them to pursue an 
unproven therapy; and c) actively cultivated and embodied through therapeutic 
experimentation and online experiential information sharing.  
The critical (hope-generating) ‘benefits’ of the liberation procedure lay in the very process of 
learning about it and researching it online, in exchanging information and experiences pre 
and post procedure, in becoming an activist or online debater on the issue, in being inspired 
to take part in formal studies or informal self-monitoring campaigns. Critical was also the 
performative turning of ‘the neurologists’, ‘the pharmaceutical industry’ and ‘mainstream MS 
medicine’ into external obstacles that needed to be overcome or sidestepped. What is more, 
the very unpredictability of the experimental procedure in which the patients decided to 
become actively involved inspired more hope than the tentative results of evidence-based 
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clinical trials about new drugs or other therapies, the latter being what biomedical experts 
might typically perceive as being more appropriately hope-generating. 
Key to ‘embodying hope’ here was the extensive and widespread sharing and aggregation of 
experiential accounts. Such practices are certainly not unique to the liberation procedure. 
They have long been recognised as being a core part of how patient activists engage with, 
both supporting and challenging, biomedical knowledge, expertise and evidence (Epstein, 
1996; Rabeharisoa et al, 2014). The distinctive contribution of this paper has been to a) 
explicitly link these practices to the question of patient decision-making and b) to reveal how 
they contribute to the generation of a logic of ‘embodied risk/hope’.  
We have analysed patients’ therapeutic experimentation and experiential information sharing 
as practices of ‘embodying hope’, which forms part of a much wider set of practices for 
cultivating hope that patients valued as a key part of their life with MS. For those who 
underwent the liberation procedure, engaging in an experimental therapy was never confined 
to simply choosing an intervention that would lead to specific physical improvements. 
Engaging in such a therapy became part of a much wider set of actions (especially those of 
sharing experiential evidence) through which patients with MS could wrest control of their 
life back from an incurable and, in their words, ‘devastating’ disease. 
Hope, along with risk, forms a crucial part of the wider anticipatory regimes of contemporary 
biomedicine and healthcare (Novas, 2006; Rhodes et al, 2009; Adams et al, 2009; Mattingly, 
2010; Petersen and Wilkinson, 2015). And while hope in such a context can be interpreted as 
‘cruel’ (Berlant, 2011), or even exploitative (Cooper and Waldby 2014), it is generally 
framed as a ‘good’ that is obtained through appropriate contact with biomedicine and 
healthcare. Appropriate is the critical word here. For when, as in the case of the liberation 
procedure, patients choose to deviate from biomedical orthodoxy and are hopeful about 
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heterodox therapies, this hope is at best accepted as a ‘placebo’ and at worst dismissed as 
‘false’ (but in both cases opposed to the realistic and beneficent hope recognised and 
endorsed by biomedical experts).    
If ‘patient choice’ is not simply a rhetorical device, but is actually to be supported and valued 
within healthcare and biomedicine, biomedical and healthcare experts of all kinds, be they 
scientists, physicians, nurses, or policy-makers (to mention but a few categories), have to 
accept that patients will, at times, make decisions that are not supported by what they as 
experts consider the best available evidence. This undoubtedly raises numerous ethical and 
professional challenges, which is a topic that deserves its own paper. However, we believe 
that a critical first step in dealing with situations where this happens, such as in the case of 
the liberation procedure, is to try to understand the logic(s) underpinning patients’ decision-
making processes.  
While critics and sceptics might automatically dismiss MS patients’ experiments with balloon 
angioplasty and stenting as rooted in an irrational form of magical thinking, and while some 
patients might genuinely believe themselves to be contributing (if only as patients) to 
innovative scientific advancement, what we argue here is that the logic that governs the 
rationality of patients’ actions and beliefs in this context is rooted in the experiential 
dimension of life with MS and needs to be analysed, understood and accepted in and on these 
terms. This is not the same as saying that one needs to respect the patient perspective or listen 
to the patient’s voice. What is necessary, and this is what we have sought to do in this paper, 
is to make intelligible the distinctive experiential logic underpinning this perspective.  
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8. Notes 
1 On the rise of medical travel (or ‘transnational healthcare’ as some, like Botterill et al 
(2013) and Bell et al (2015), prefer to call it) as well as the widespread attention it has 
received from the media, academics, medical practitioners and policy makers see Turner 
(2007), Murdoch and Scott (2010), Whittaker et al (2010). 
2 See, for example, the Grady (2010), the BBC (2011), Ubelacker (2012), and Fayerman 
(2013), for such coverage of patients’ responses to the theory and intervention.  
3 Our use of ‘logic’ is not meant to imply that the patients’ decisions were ‘logical’ or 
‘rational’ in the sense that we have judged them to be ‘justified’ or ‘sound’. Rather we use the 
terms to signify that the practices we analyse have an internal coherence, albeit one that 
differs from the dominant logics of biomedicine. There are a number of alternative social 
scientific terms and concepts that we could have drawn on here, such as discourse, mode of 
ordering, regime or style. Taking inspiration from Annemarie Mol’s use of the term (Mol, 
2008; p.8), we use logic to indicate that the practices we explore have an underlying, if 
contingent and fragile, rationality that holds them together, linking words, practices, and 
materialities in particular situated ways. In addition, we chose to use logic over other possible 
alternatives because it chimes with how our interviewees described their decision-making 
practices and would be recognisable to them.  
4 A number of private medical ‘tourist’ clinics in countries such as Poland, Bulgaria, India, 
and Cost Rica offered the intervention. It was available privately in the US and UK (in some 
cases as part of research studies, although patients still had to pay). Initially, if the patient 
could find an interventional radiologist willing to perform the procedure it was available in 
Australia, but finding someone willing to do so was not easy. As the intervention gained 
increased media attention and become more controversial many of the radiologists and clinics 
that offered it stopped doing so. Costs varied greatly depending on country, radiologist, 
number of angioplasties and/or stents and could be anywhere between $10,000 and $15,000 
per procedure, excluding travel and accommodation.  
5 Zamboni initially proposed the idea that vascular abnormalities might play a role in MS in 
2006 (Zamboni, 2006). However, it was with the publication of the research studies in 2009 
that his work started to receive widespread international attention from patient groups, the 
media, and MS researchers. 
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6 For the FDA’s warning about CCSVI and the liberation procedure see FDA (2012); for 
NICE’s guidance see NICE (2012); for the systematic review and advice of the CIHR see 
CIHR (2011).   
7 At the time of writing, the most recent update on CCSVI-related research was a presentation 
given by Anthony Traboulsee (Associate Professor of Neurology at the University of British 
Columbia) at the Society for Interventional Radiology’s annual scientific meeting on the 8th 
of March 2017. Based on an unpublished double-blinded trial of 104 people with MS, the 
study found no association between venous angioplasty and improvement in MS symptoms 
48 weeks post the intervention (Mulholland, 2017). Zamboni’s much awaited BRAVE 
DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis) trial has yet to 
be completed (http://bravedreams.ccsvi-sm.org/).While support for the liberation procedure 
has dwindled, many people believe the intervention had a positive effect on their health and 
activists continue to support further research. For example, the CCSVI Alliance 
(http://ccsvi.org/), the Canadian Neurovascular Health Society (http://www.cnhs.ca/) and 
CCSVI Australia (http://ccsviaustralia.com.au/).  
8 Natalizumab, a DMD for highly active MS. 
9 An opioid believed to have a positive effect on the immune system. 
10 Compare with Petersen et al, (2014; p.675) and Prasad (2015; p.141). 
11 The question of what medical specialism and expertise is best suited to researching and 
treating MS is a long-standing one and has been the cause of divisions in the field in the past. 
For more on the wider historical context of such debates see Nicolson and McLaughlin 
(1988) and Nicolson and Lowis (2002). 
12 We use ‘regime of truth’ here to indicate particular logics and associated forms of 
evidence, rather than the full Foucauldian sense of the term (Foucault, 1991). 
13 Although MS is not strictly speaking a genetic disease, it has long been believed that there 
is a genetic component. For more on genetics in MS see Hoppenbrouwers and Hintzen 
(2011). 
14 Titled ‘The Liberation Treatment: A whole new approach to MS’, this documentary was 
aired in November 2009 on CTV news’ current affairs programme W5 
(http://www.ctvnews.ca/the-liberation-treatment-a-whole-new-approach-to-ms-1.456617). 
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15 Video available at: https://www.youtube.com/watch?v=pjOvd4PBnoo, accessed 12 
November 2016.  
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